Ask AI
ProCE Banner Series

Exploring the Progress and Evolving Therapeutic Paradigm in Multiple Myeloma

Join us either in-person or virtually for this interactive, CME-certified symposium held in conjunction with the 2023 ASCO Annual Meeting featuring expert perspectives on the evolving therapeutic paradigm in multiple myeloma. Bring your questions for the live Q&A session with the expert panel at the end of the session.

To Register: Please click the green “Learn More” button below. On the next page, select either Register for In-Person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

  AMA
Credits Available

2.0

Who Should Attend

This educational program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

All Events

Exploring the Progress and Evolving Therapeutic Paradigm in Multiple Myeloma

Past Events

June

03

2023

7:00 PM - 9:00 PM Central Time (CT)

In-personVirtual

Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 60605

Topics

Exploring the Progress and Evolving Therapeutic Paradigm in Multiple Myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to educate hematologists, oncologists, and other healthcare professionals, about recent developments in the treatment of multiple myeloma to optimally individualize therapy. 

Target Audience
This educational program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate emerging clinical data on novel therapeutics and combination treatment strategies for patients with multiple myeloma
  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnostic and staging criteria
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Select therapeutic strategies with new and emerging agents and novel combination regimens for patients with relapsed/refractory multiple myeloma based on available data, expert recommendations, and individual patient and disease characteristics
  • Identify patients who may be eligible to enroll on a clinical trial of investigational therapies or combination regimens to treat multiple myeloma at all stages of the disease

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AbbVie Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; Legend Biotech USA; and Pfizer Inc.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191